» Articles » PMID: 32690502

Quality of Advertisements for Prescription Drugs in Family Practice Medical Journals Published in Australia, Canada and the USA with Different Regulatory Controls: a Cross-sectional Study

Overview
Journal BMJ Open
Specialty General Medicine
Date 2020 Jul 22
PMID 32690502
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To assess if different forms of regulation lead to differences in the quality of journal advertisements.

Design: Cross-sectional study.

Participants: Thirty advertisements from family practice journals published from 2013 to 2015 were extracted for three countries with distinct regulatory pharmaceutical promotion systems: Australia, Canada and the USA.

Primary And Secondary Outcome Measures: Advertisements under each regulatory system were compared concerning three domains: information included in the advertisement, references to scientific evidence and pictorial appeals and portrayals. An overall ranking for advertisement quality among countries was determined using the first two domains as the information assessed has been associated with more appropriate prescribing.

Results: Advertisements varied significantly for number of claims with quantitative benefit (Australia: 0.0 (0.0-3.0); Canada: 0.0 (0.0-5.0); USA: 1.0 (0.0-6.0); p=0.01); statistical method used in reporting benefit (relative risk reduction, absolute risk reduction and number needed to treat; Australia: 6.7%, n=2; Canada: 10.0%, n=3; USA: 36.6%, n=11; p=0.02); mention of adverse effects, warnings or contraindications (Australia: 13.3%, n=4; Canada: 23.3%, n=7; USA: 53.3%, n=16; p=0.002); equal prominence between safety and benefit information (Australia: 25.0%, n=1; Canada: 28.6%, n=2; USA: 75.0%, n=12; p=0.04); and methodological quality of references score (Australia: 0.4150 (0.25-0.70); Canada: 0.25 (0.00-0.63); USA: 0.25 (0.00-0.75); p<0.001). The USA ranked first, Canada second and Australia third for overall quality of journal advertisements. Significant differences for humour appeals (Australia: 3.3%, n=1; Canada: 13.3%, n=4; USA: 26.7%, n=8; p=0.04), positive emotional appeals (Australia: 26.7%, n=8; Canada: 60.0%, n=18; USA: 50.0%, n=15; p=0.03), social approval portrayals (Australia: 0.0%, n=0; Canada: 0.0%, n=0; USA: 10.0%, n=3; p=0.04) and lifestyle or work portrayals (Australia: 43.3%, n=13; Canada: 50.0%, n=15; USA: 76.7%, n=23; p=0.02) were found among countries.

Conclusions: Different regulatory systems influence journal advertisement quality concerning all measured domains. However, differences may also be attributed to other regulatory, legal, cultural or health system factors unique to each country.

Citing Articles

Pharmaceutical policies: effects of policies regulating drug marketing.

Fulone I, Cadogan C, Barberato-Filho S, Bergamaschi C, Mazzei L, Lopes L Cochrane Database Syst Rev. 2023; 6:CD013780.

PMID: 37288951 PMC: 10250001. DOI: 10.1002/14651858.CD013780.pub2.


Complaints about Violations of Voluntary and Pharmaceutical Industry-Run Medicine Promotion Codes in Canada.

Lexchin J Int J Soc Determinants Health Health Serv. 2023; 53(4):518-527.

PMID: 36938584 PMC: 10631264. DOI: 10.1177/27551938231165158.


Knowledge and Practice of Antibiotic Management and Prudent Prescribing among Polish Medical Doctors.

Zgliczynski W, Bartosinski J, Rostkowska O Int J Environ Res Public Health. 2022; 19(6).

PMID: 35329427 PMC: 8954040. DOI: 10.3390/ijerph19063739.


Policing the promotion of prescription medicines - the new Medicines Australia Code of Conduct.

Mintzes B Aust Prescr. 2021; 44(1):4-5.

PMID: 33664540 PMC: 7900277. DOI: 10.18773/austprescr.2020.082.


Promotion or education: a content analysis of industry-authored oral health educational materials targeted at acute care nurses.

Grundy Q, Millington A, Cussen C, Held F, Dale C BMJ Open. 2020; 10(11):e040541.

PMID: 33247018 PMC: 7703418. DOI: 10.1136/bmjopen-2020-040541.

References
1.
Frosch D, Krueger P, Hornik R, Cronholm P, Barg F . Creating demand for prescription drugs: a content analysis of television direct-to-consumer advertising. Ann Fam Med. 2007; 5(1):6-13. PMC: 1783924. DOI: 10.1370/afm.611. View

2.
Schwartz L, Woloshin S . Medical Marketing in the United States, 1997-2016. JAMA. 2019; 321(1):80-96. DOI: 10.1001/jama.2018.19320. View

3.
Villanueva P, Peiro S, Librero J, Pereiro I . Accuracy of pharmaceutical advertisements in medical journals. Lancet. 2003; 361(9351):27-32. DOI: 10.1016/S0140-6736(03)12118-6. View

4.
Bosco J, Silliman R, Thwin S, Geiger A, Buist D, Prout M . A most stubborn bias: no adjustment method fully resolves confounding by indication in observational studies. J Clin Epidemiol. 2009; 63(1):64-74. PMC: 2789188. DOI: 10.1016/j.jclinepi.2009.03.001. View

5.
Najman J, Siskind V, Bain C . Prescription drug advertising: medical journal practices under different types of control. Med J Aust. 1979; 1(10):420-4. DOI: 10.5694/j.1326-5377.1979.tb127012.x. View